Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2025-12-28 @ 6:14 PM
Study NCT ID:
NCT05631093
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-21
First Post:
2022-11-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2028-07-11
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-18
First Submit QC Date:
None
Study First Post Date:
2022-11-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-09-29
Results First Submit QC Date:
None
Results First Post Date:
2025-11-21
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-11
Last Update Post Date:
2025-11-21
Last Update Post Date Type:
ESTIMATED